CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and expanded oncology plans.

In a new study, scientists at the Max Planck Institute for Evolutionary Anthropology in Leipzig analyzed the impact of more ...

Precise tumor diagnosis and treatment require the support of abundant molecular information. However, conventional molecular ...

Scientists from Kolkata-based Bose Institute have created GlowCas9 -- a CRISPR protein that lights up while performing gene ...

CRISPR biosensors enable real-time health monitoring with attomolar sensitivity, wearable integration, and multiplex ...

A new study from the Max Planck Institute for Evolutionary Anthropology examined how > 2,000 clinically approved drugs affect ...

Large-scale drug atlas uncovers new genome editing modulators and potential therapeutic strategies for DNA repair-deficient cancers ...

Scientists have utilised revolutionary DNA base editing to treat previously incurable T-cell acute lymphoblastic leukaemia.

Earlier this week, CRISPR Therapeutics reported encouraging early-stage clinical data for its allogeneic CD19 CAR T therapy, zugo-cel, in aggressive B-cell lymphoma and autoimmune diseases, and ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA ...